PRAX
Praxis Precision Medicines, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +6.2% ·
aandelenstroom +10.5% ·
netto nieuwe posities 0.0%
· formule
Brede accumulatie: stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 905 | $238,513 | n/a | n/a |
| Q2 2026 | 110 | +10 | 16.58M | $5.55B | +16 | −6 |
| Q1 2026 | 103 | +2 | 17.55M | $5.65B | +11 | −10 |
| Q4 2025 | 101 | +1 | 18.04M | $5.32B | +2 | n/a |
| Q3 2025 | 17 | +1 | 10.82M | $573.60M | +1 | −1 |
| Q2 2025 | 14 | 0 | 8.51M | $357.72M | +1 | −1 |
| Q1 2025 | 11 | -2 | 4.62M | $175.13M | n/a | −2 |
| Q4 2024 | 13 | 0 | 4.07M | $313.25M | n/a | n/a |
| Q3 2024 | 12 | 0 | 3.95M | $227.16M | +1 | −1 |
| Q2 2024 | 12 | n/a | 4.09M | $168.97M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 2.37M | +20.2% | $125.83M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passief) | 1.80M | +13.3% | $95.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×13 |
| 3 | Point72 Asset Management ✦ | 1.50M | +56.8% | $79.29M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passief) | 1.27M | +4.2% | $67.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 5 | T. Rowe Price ✦ | 1.00M | -31.9% | $53.19M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passief) | 907.11K | +29.9% | $48.08M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Morgan Stanley ✦ | 643.50K | n/a | $34.11M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 8 | Goldman Sachs Group ✦ | 593.02K | n/a | $31.43M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (passief) | 457.03K | +1.2% | $24.23M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Marshall Wace ✦ | 68.14K | Nieuw | $3.61M | 0.0% | New | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 61.24K | +9.6% | $3.25M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 12 | JPMorgan Chase ✦ | 52.42K | n/a | $2.78M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 13 | Fidelity (FMR) ✦ | 43.21K | +13.4% | $2.29M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 21.90K | +50.2% | $1.16M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 15 | D. E. Shaw & Co. ✦ | 19.80K | +3.9% | $1.05M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 16 | Citadel Advisors ✦ | 7.80K | -24.8% | $413,294 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 5.51K | -15.4% | $291,924 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Marshall Wace | $3.61M | 0.0% |
Verlaten
| Norges Bank | $210,250 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 287 houders, 28.34M aandelen, $8.85B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.